SCHEMBL25368459

SCHEMBL25368459

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)Nc3cccc(OC(F)(F)F)c3)cs2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ DHX9 Q08211 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ SLC22A12 Q96S37 1/20 0.47
▸ ABL1 P00519 1/20 0.46
▸ HPGD P15428 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ P2RX1 P51575 1/20 0.45
▸ PTPN1 P18031 1/20 0.44
▸ CBLB Q13191 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543864 1.00 NPC1 (0.52) NPC1RAB9ADHX9LMNASMN1; SMN2
SCHEMBL25367752 0.93 ABL1 (0.55) NPC1RAB9ADHX9LMNASMN1; SMN2
SCHEMBL30544016 0.93 ABL1 (0.55) NPC1RAB9ADHX9LMNASMN1; SMN2
SCHEMBL30543904 0.87 DHX9 (0.50) NPC1RAB9ADHX9LMNASMN1; SMN2
SCHEMBL25368623 0.87 DHX9 (0.50) NPC1RAB9ADHX9LMNASMN1; SMN2
SCHEMBL25368280 0.84 DHX9 (0.53) RAB9ADHX9LMNASMN1; SMN2HPGD
SCHEMBL30543946 0.84 DHX9 (0.53) RAB9ADHX9LMNASMN1; SMN2HPGD
SCHEMBL25367472 0.83 MEN1 (0.53) RAB9ADHX9HPGDALDH1A1GAA
SCHEMBL30543926 0.83 MEN1 (0.53) RAB9ADHX9HPGDALDH1A1GAA
SCHEMBL25368034 0.82 KMT2A (0.60) NPC1RAB9ADHX9LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B NPC1 2484/4885RAB9A 388/4885DHX9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback